These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 20401891)

  • 1. Two functions, one molecule: a metal-binding and a targeting moiety to combat Alzheimer's disease.
    Hureau C; Sasaki I; Gras E; Faller P
    Chembiochem; 2010 May; 11(7):950-3. PubMed ID: 20401891
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyloid-beta, BACE, and oxidative stress in Alzheimer's disease, a commentary on "The different aggregation state of beta-amyloid 1-42 mediates different effects on oxidative stress, neurodegeneration and BACE-1 expression".
    Lee HG; Perry G; Zhu X; Nunomura A; Smith MA
    Free Radic Biol Med; 2006 Jul; 41(2):188-9. PubMed ID: 16814097
    [No Abstract]   [Full Text] [Related]  

  • 3. The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease.
    Crouch PJ; White AR; Bush AI
    FEBS J; 2007 Aug; 274(15):3775-83. PubMed ID: 17617225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease sends the wrong signals--a perspective.
    Neve RL
    Amyloid; 2008 Mar; 15(1):1-4. PubMed ID: 18266116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
    Mancino AM; Hindo SS; Kochi A; Lim MH
    Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease.
    Atwood CS; Huang X; Moir RD; Tanzi RE; Bush AI
    Met Ions Biol Syst; 1999; 36():309-64. PubMed ID: 10093929
    [No Abstract]   [Full Text] [Related]  

  • 7. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease.
    Rodríguez-Rodríguez C; Sánchez de Groot N; Rimola A; Alvarez-Larena A; Lloveras V; Vidal-Gancedo J; Ventura S; Vendrell J; Sodupe M; González-Duarte P
    J Am Chem Soc; 2009 Feb; 131(4):1436-51. PubMed ID: 19133767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological metals and Alzheimer's disease: implications for therapeutics and diagnostics.
    Duce JA; Bush AI
    Prog Neurobiol; 2010 Sep; 92(1):1-18. PubMed ID: 20444428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of oxidant mechanisms in Alzheimer's disease.
    Moreira PI; Smith MA; Zhu X; Santos MS; Oliveira CR; Perry G
    Expert Rev Neurother; 2004 Nov; 4(6):995-1004. PubMed ID: 15853526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
    Varadarajan S; Yatin S; Aksenova M; Butterfield DA
    J Struct Biol; 2000 Jun; 130(2-3):184-208. PubMed ID: 10940225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease.
    Butterfield DA
    Chem Res Toxicol; 1997 May; 10(5):495-506. PubMed ID: 9168246
    [No Abstract]   [Full Text] [Related]  

  • 12. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis.
    Dedeoglu A; Cormier K; Payton S; Tseitlin KA; Kremsky JN; Lai L; Li X; Moir RD; Tanzi RE; Bush AI; Kowall NW; Rogers JT; Huang X
    Exp Gerontol; 2004; 39(11-12):1641-9. PubMed ID: 15582280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
    Zetterberg H
    Scand J Clin Lab Invest; 2009; 69(1):18-21. PubMed ID: 19199126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of Alzheimer's disease].
    Ishiura S; Hattori C
    Tanpakushitsu Kakusan Koso; 2004 Nov; 49(14):2179-85. PubMed ID: 15559301
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer's amyloid beta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide.
    Butterfield DA; Bush AI
    Neurobiol Aging; 2004; 25(5):563-8. PubMed ID: 15172731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The increased activity of BACE1 correlates with oxidative stress in Alzheimer's disease.
    Borghi R; Patriarca S; Traverso N; Piccini A; Storace D; Garuti A; Gabriella Cirmena ; Patrizio Odetti ; Massimo Tabaton
    Neurobiol Aging; 2007 Jul; 28(7):1009-14. PubMed ID: 16769154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's disease.
    Querfurth HW; LaFerla FM
    N Engl J Med; 2010 Jan; 362(4):329-44. PubMed ID: 20107219
    [No Abstract]   [Full Text] [Related]  

  • 18. Translational control of BACE1 may go awry in Alzheimer's disease.
    Wong PC
    Neuron; 2008 Dec; 60(6):941-3. PubMed ID: 19109900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gamma-secretase: a complex target for Alzheimer's disease.
    Lundkvist J; Näslund J
    Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?
    Murphy MP; Golde TE
    Neurology; 2006 Jan; 66(2 Suppl 1):S65-8. PubMed ID: 16432148
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.